Evogliptin - CAS 1222102-29-5

Evogliptin (DA-1229) is a DPP4 inhibitor with oral activity. Evogliptin has significant and lasting hypoglycemic effect in mouse model. Evogliptin inhibits the production of the fibrosis and inflammatory in hepatocytes signals by inducing autophagy. Evogliptin can be used to study type 2 diabetes, chronic liver inflammation, osteoporosis and renal impairment.

Proteasome, Autophagy, Others

Proteases/Proteasome, Ubiquitination, Others, Autophagy

1222068

C19H26F3N3O3

401.42

C(C[C@@H](CC1=C(F)C=C(F)C(F)=C1)N)(=O)N2[C@H](COC(C)(C)C)C(=O)NCC2

-20°C

Ice Packs

Small Compound